Articles by #hashtag


9 hits

Gedeon Richter: Q4 Loss and Competitive Disadvantage

Feb 28, 2023

The Hungarian pharmaceutical company Gedeon Richter Plc. presented its results for the year 2022 this Tuesday. The report caused a price drop on the stock market, as it turned out that the always massively profitable company turned loss-making in the last quarter of the year (due to the special tax and the exchange rate change). […]

Richter and Mithra Sign Licence Agreement

Feb 15, 2023

Gedeon Richter Plc. and Mithra Pharmaceuticals have announced that they signed a license agreement for the commercialisation of Donesta®, a novel product candidate for the treatment of post-menopausal symptoms, according to a statement on the website of the Budapest Stock Exchange. The completion of the agreement follows the signing of the Binding Term Sheet by […]

Richter Acquires Company in Ireland

Feb 7, 2023

The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that it has acquired from shareholders of Consilient Health 100% control of OC Distributors Ltd., an Ireland based company holding the marketing and distribution rights of a number of women’s healthcare products. The transaction value is GBP 32.5 […]

Pécs University: Funding for Unique Tool, R&D Center

Feb 3, 2023

The University of Pécs (PTE) and the pharma firm Gedeon Richter Plc. (Richter) are creating an infrastructure and professional knowledge base worth more than HUF five billion in cooperation, which can be used in the fields of pharmaceutical research and agricultural science, among others, and is also suitable for the structural analysis of macromolecules, the […]

HUF 28 Bn Special Tax by Gedeon Richter in 2022

Dec 27, 2022

The Hungarian pharmaceutical giant Gedeon Richter Plc. has published an extraordinary announcement on the website of the Budapest Stock Exchange that under a new government decree on the extra profit taxes, the magnitude of supplementary pharmaceutical tax payable by the company for the year 2022 is expected to be approximately HUF 28 billion. “On June […]

Further FDA Approval for Gedeon Richter Drug

Dec 19, 2022

The Hungarian pharma company Gedon Richter’s partner AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR® (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for […]

Gedeon Richter Chief of Operations Resigns

Nov 15, 2022

The Hungarian pharmaceutical firm Gedeon Richter Plc. has announced an important change in the executive management of company on the website of the Budapest Stock Exchange. “The company hereby informs its honorable shareholders that with effect from November 15, 2022 Mr. Erik Bogsch resigns from his position regarding the direct supervision of Commercial, International and […]

Gedeon Richter Closes R&D Project of Nearly HUF 5 Bn

Nov 2, 2022

Richter Gedeon Plc. has built and equipped a new molecular biology laboratory at its Debrecen site. The investment was part of a multi-year, partly EU-funded, HUF 4.83 billion research and development (R&D) project to support biotechnology drug development, the Budapest-listed pharmaceutical company told the state news agency MTI on Monday. According to the statement, the […]

Richter Submission for the Treatment of Endometriosis

Oct 25, 2022

Hungarian phrama company Gedeon Richter Plc. has announced that it has submitted a Type II Variation application for RYEQO® to the European Medicines Agency (EMA) for the treatment of moderate to severe pain associated with endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis. RYEQO® […]

© Copyright 2023 Duax Kft. –  All rights reserved.